Atlas Trials

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Clinical trial NCT03639987 · TERMINATED

Trial details

NCT number
NCT03639987
Sponsor
Biogen
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Cognitive DysfunctionAlzheimer's Disease
Start date
2018-12-20
Primary completion
2019-07-30
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.